Addition of Cisplatin to Irinotecan Not Effective for Second-Line Gastric Cancer
No survival benefit was observed upon adding cisplatin to irinotecan after S-1 monotherapy failure in patients with advanced gastric cancer.
No survival benefit was observed upon adding cisplatin to irinotecan after S-1 monotherapy failure in patients with advanced gastric cancer, a recent study published online in the European Journal of Cancer has shown.
Because the optimal second-line regimen for treating advanced gastric cancer remains unclear, researchers sought to examine the survival benefit of cisplatin plus irinotecan compared with irinotecan monotherapy in patients initially treated with S-1, an oral fluoropyrimidine, monotherapy.
Researchers enrolled 68 patients with advanced gastric cancer and 95 with recurrent gastric cancer. Patients were randomly assigned to receive cisplatin 30mg/m2 plus irinotecan 60mg/m2 every 2 weeks or irinotecan 150mg/m2 every 2 weeks alone.
Results showed that the median overall survival was 13.9 months (95% CI: 10.8-17.6) for the combination group versus 12.7 months (95% CI: 10.3-17.2) for the irinotecan group (HR = 0.834; 95% CI: 0.596-1.167; P = 0.288).
Researchers found no significant differences in progression-free survival or response rate between both groups.
RELATED: MK-2206 Not Effective in Gastric, Gastroesophageal Junction Cancers
An exploratory subgroup analysis, however, showed that cisplatin plus irinotecan was significantly more effective for those with intestinal-type advanced gastric cancer compared with irinotecan monotherapy (OS: 15.8 vs 14.0 months;P = 0.019).
In regard to safety, the combination group had a higher incidence of grade 3-4 anemia and elevated serum lactate dehydrogenase levels compared with irinotecan alone.